Vascular injury in coronary, cerebral, and peripheral arteries evokes local platelet activation, recruitment and thrombotic occlusion, reversal of which presents a major therapeutic challenge. Platelets are consistently unresponsive to agonists in the presence of endothelial cells (EC), even in the absence of eicosanoids and nitric oxide. This observation culminated in our characterization of endothelial cell CD39/ecto-ADPase as the prime thromboregulator. CD39 rapidly metabolizes ADP released from activated platelets, thereby abolishing aggregation and recruitment. A recombinant, soluble form of human CD39, solCD39, was developed which potently blocked agonist-induced human platelet aggregation in vitro, and prolongs bleeding time in mice in vivo. CD39 -/- mice exhibited a latent prothrombotic phenotype with increased susceptibility to ischemic cerebral thrombosis and injury, demonstrating a critical role for CD39 in cerebral thromboregulation. This collaboration will decipher the pivotal biological role of endogenous CD39 in inhibiting ischemic-driven thrombosis, and will develop CD39 as a novel antithrombotic agent. Structure-function studies will: Develop specific information about the CD39 active site, to identify which amino acids are required for enzyme catalysis; Map critical regions in CD39 which contribute to its tertiary structure; Establish the contribution of glycosylation to CD39 enzymatic activity; Determine biophysical and structural properties of solCD39 to comprehend mechanisms of nucleotide dephosphorylation; Generate multivalent derivatives of the extracellular domain of CD39 to define the structural basis for oligomerization-mediated promotion of enzymatic activity. The role of endogenous CD39 in microvascular thrombosis will be studied in CD39 -/- mice, subjected to ischemic stroke with or without reconstitution with solCD39. SolCD39 will also be investigated as a potential therapeutic agent in an established baboon model of ischemic stroke. Using endothelial cells from control and CD39 -/- mice, as well as ischemic murine and baboon brain tissue, ischemia- or hypoxia-driven modulation of CD39 expression will be studied. The research represents a multidisciplinary approach to understanding the critical role of CD39 as the prime regulator of platelet-mediated occlusive arterial thrombosis. This collaboration, based on compelling feasibility data and historical collaborative success, will advance the understanding of CD39 thromboregulation, and lead to a novel therapeutic agent for thrombotic diatheses.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS041460-02
Application #
6394432
Study Section
Special Emphasis Panel (ZHL1-CSR-B (M1))
Program Officer
Jacobs, Tom P
Project Start
2000-09-30
Project End
2005-08-31
Budget Start
2001-09-01
Budget End
2002-08-31
Support Year
2
Fiscal Year
2001
Total Cost
$426,250
Indirect Cost
Name
Columbia University (N.Y.)
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
167204994
City
New York
State
NY
Country
United States
Zip Code
10032
Hyman, Matthew C; Petrovic-Djergovic, Danica; Visovatti, Scott H et al. (2009) Self-regulation of inflammatory cell trafficking in mice by the leukocyte surface apyrase CD39. J Clin Invest 119:1136-49
Prince, Jose M; Ming, Mei Jian; Levy, Ryan M et al. (2007) Early growth response 1 mediates the systemic and hepatic inflammatory response initiated by hemorrhagic shock. Shock 27:157-64
Mocco, J; Mack, William J; Ducruet, Andrew F et al. (2006) Complement component C3 mediates inflammatory injury following focal cerebral ischemia. Circ Res 99:209-17
Marcus, Aaron J; Broekman, M Johan; Drosopoulos, Joan H F et al. (2005) Role of CD39 (NTPDase-1) in thromboregulation, cerebroprotection, and cardioprotection. Semin Thromb Hemost 31:234-46
Ten, Vadim S; Sosunov, Sergei A; Mazer, Sean P et al. (2005) C1q-deficiency is neuroprotective against hypoxic-ischemic brain injury in neonatal mice. Stroke 36:2244-50
Mack, William J; Komotar, Ricardo J; Mocco, J et al. (2003) Serial magnetic resonance imaging in experimental primate stroke: validation of MRI for pre-clinical cerebroprotective trials. Neurol Res 25:846-52
Marcus, Aaron J; Broekman, M Johan; Drosopoulos, Joan H F et al. (2003) Metabolic control of excessive extracellular nucleotide accumulation by CD39/ecto-nucleotidase-1: implications for ischemic vascular diseases. J Pharmacol Exp Ther 305:9-16
Mocco, J; Choudhri, Tanvir; Huang, Judy et al. (2002) HuEP5C7 as a humanized monoclonal anti-E/P-selectin neurovascular protective strategy in a blinded placebo-controlled trial of nonhuman primate stroke. Circ Res 91:907-14
Ten, Vadim S; Pinsky, David J (2002) Endothelial response to hypoxia: physiologic adaptation and pathologic dysfunction. Curr Opin Crit Care 8:242-50
D'Ambrosio, Anthony L; Hoh, Daniel J; Mack, William J et al. (2002) Interhemispheric intracranial pressure gradients in nonhuman primate stroke. Surg Neurol 58:295-301; discussion 301

Showing the most recent 10 out of 13 publications